The expanded commercialization agreement aims to increase availability of the GlycoKnow Ovarian laboratory-developed test through Aranscia's clinical workflow and technology platforms.
The company’s product, Slideflow Pro, is a scalable and modular platform designed to analyze digitized pathology slides and support the development of AI-based biomarkers that can help answer clinically important questions in cancer care.
The companion diagnostic evaluates mismatch repair deficiency, a predictive biomarker used to identify patients who may respond to PD-1-targeted therapies.
The updated test includes additional DPYD variants recommended by the Association for Molecular Pathology to help identify patients who may be at risk for severe chemotherapy side effects.
Read More
New clinical utility data showed that offering a blood-based lung cancer test increased screening participation compared with low-dose CT screening alone.
Read More
Monitoring circulating tumor DNA dynamics outperformed standard markers for predicting survival and relapse in early-stage patients.
Read More
The study demonstrated that patients who test positive for ctDNA “actually benefit from chemotherapy.”
Read More
Research shows optical genome mapping identifies genomic changes in nearly 98% of T-cell acute lymphoblastic leukemia cases compared to 55% with traditional analysis.
Read More
The digital pathology platform provides patient-specific risk estimates to help clinicians tailor treatment for metastatic hormone-sensitive disease.
Read More
Results from the NHS-Galleri study show a 26% reduction in metastatic cancer diagnoses by the third round of screening.
Read More
The diagnostic test identifies specific genetic mutations to help select patients for a targeted therapy combination.
Read More
The test uses a new approach to identify signs of cancer recurrence with faster result times for healthcare providers and patients.
Read More
Clinical results show high sensitivity for colorectal cancer relapse and ultra-low detection limits for lung cancer.
Read More
The tissue- and blood-based tests identify patients with specific gene mutations who may benefit from a combination therapy.
Read More
Results from the PATHFINDER 2 trial show the Galleri test identifies 6.5 times more cancers when used with standard screenings.
Read More
The authorization from the New York State Department of Health makes the screening test available in all 50 states.
Read More
The multicenter study will evaluate proactive outreach to at-risk relatives and the impact of multigene panel testing on patient care.
Read More
The study identifies HAVCR1 as a tool for earlier detection and treatment monitoring for primary central nervous system lymphoma.
Read More